These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16955463)

  • 1. Successful self-infusion of activated prothrombin complex concentrate for prophylaxis in a child with a factor VIII inhibitor.
    Ohga S; Nomura A; Takada H; Suga N; Hara T
    Am J Hematol; 2007 Feb; 82(2):145-9. PubMed ID: 16955463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
    Valentino LA
    Haemophilia; 2010 Mar; 16(2):263-71. PubMed ID: 20028421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.
    Villarrubia R; Oyagüez I; Álvarez-Román MT; Mingot-Castellano ME; Parra R; Casado MA
    Haemophilia; 2015 May; 21(3):320-329. PubMed ID: 25855214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of prophylactic treatment with activated prothrombin complex concentrate in a patient with inhibitor-positive hemophilia A.
    Nakamura S; Morimoto A; Oh Y; Hayase T; Kashii Y; Gunji Y; Momoi MY
    Blood Coagul Fibrinolysis; 2012 Apr; 23(3):235-7. PubMed ID: 22322137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors.
    Leissinger CA; Becton DL; Ewing NP; Valentino LA
    Haemophilia; 2007 May; 13(3):249-55. PubMed ID: 17498073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors.
    Leissinger C; Gringeri A; Antmen B; Berntorp E; Biasoli C; Carpenter S; Cortesi P; Jo H; Kavakli K; Lassila R; Morfini M; Négrier C; Rocino A; Schramm W; Serban M; Uscatescu MV; Windyga J; Zülfikar B; Mantovani L
    N Engl J Med; 2011 Nov; 365(18):1684-92. PubMed ID: 22047559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series.
    Ettingshausen CE; Kreuz W
    Haemophilia; 2010 Jan; 16(1):90-100. PubMed ID: 19878335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors.
    Antunes SV; Tangada S; Stasyshyn O; Mamonov V; Phillips J; Guzman-Becerra N; Grigorian A; Ewenstein B; Wong WY
    Haemophilia; 2014 Jan; 20(1):65-72. PubMed ID: 23910578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study.
    Zanon E; Milan M; Gamba G; Ambaglio C; Saggiorato G; Spiezia L; Montani N; Prandoni P
    Thromb Res; 2015 Dec; 136(6):1299-302. PubMed ID: 26505666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A decade-long clinical experience on the prophylactic use of activated prothrombin complex concentrate in acquired haemophilia A: a case series from a tertiary care centre.
    Árokszállási A; Rázsó K; Ilonczai P; Oláh Z; Bereczky Z; Boda Z; Schlammadinger Á
    Blood Coagul Fibrinolysis; 2018 Apr; 29(3):282-287. PubMed ID: 29474202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Successful treatment by switching from activated prothrombin complex concentrate to emicizumab therapy in a hemophilia A patient with inhibitors].
    Sakamoto A; Nakadate H; Watanabe N; Ishiguro A
    Rinsho Ketsueki; 2020; 61(6):617-620. PubMed ID: 32624534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent intramural hematoma of the small intestine in a severe hemophilia A patient with a high titer of factor VIII inhibitor: a case report and review of the literature.
    Katsumi A; Matsushita T; Hirashima K; Iwasaki T; Adachi T; Yamamoto K; Kojima T; Takamatsu J; Saito H; Naoe T
    Int J Hematol; 2006 Aug; 84(2):166-9. PubMed ID: 16926140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of bleeding in hemophilia patients with high-titer inhibitors.
    Leissinger CA; Konkle BA; Antunes SV
    Expert Rev Hematol; 2015 Jun; 8(3):375-82. PubMed ID: 25937074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contact activation and factor VII after the use of an activated prothrombin complex concentrate (FEIBA) in hemophiliacs with inhibitors.
    Mariani G; Bouma BN; Mazzucconi MG; Avvisati G; Di Nucci GD; Corrao D; Mandelli F
    Thromb Res; 1983 Aug; 31(3):475-88. PubMed ID: 20218003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of non-activated prothrombin complex concentrate (Proplex ST) on intraperitoneal hematoma in a hemophilia A patient with a factor VIII inhibitor.
    Kagawa H; Yasuzawa M; Ozaki Y; Yamamoto Y; Katsurada T; Nomura S; Okubo S; Fukuhara S
    Intern Med; 1996 Apr; 35(4):319-22. PubMed ID: 8739790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease.
    Hilgartner MW; Makipernaa A; Dimichele DM
    Haemophilia; 2003 May; 9(3):261-8. PubMed ID: 12694515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
    Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
    Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial.
    Sjamsoedin LJ; Heijnen L; Mauser-Bunschoten EP; van Geijlswijk JL; van Houwelingen H; van Asten P; Sixma JJ
    N Engl J Med; 1981 Sep; 305(13):717-21. PubMed ID: 6790990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].
    Shima M; Sawamoto Y; Kamisue M; Shibata Y; Tuzi S; Kuwabara M; Tanaka I; Tanizawa T; Tanaka A; Ueda M; Kakishita E; Yoshioka A
    Rinsho Ketsueki; 1996 Nov; 37(11):1303-8. PubMed ID: 8960666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors.
    Ewing N; Escuriola-Ettingshausen C; Kreuz W
    Haemophilia; 2015 May; 21(3):358-364. PubMed ID: 25603840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.